No Data
No Data
No Data
No Data
No Data
東曜藥業-B:2023年年報
Futu NewsApr 26 18:01 · Announcements
Dongyao Pharmaceutical-B (1875.HK): Park Hin-ting is growing rapidly, and the ADC CDMO business has obvious advantages
Commentary opinion: The commercialization of listed products has been promoted smoothly, and performance has grown rapidly: the company's revenue in 2023 was 781 million yuan, an increase of 77% over the previous year, and the net loss was drastically reduced to 37.76 million yuan, a decrease of 25% over the previous year.
國元國際Mar 20 00:00
Featured announcements | Fuyao Glass's net profit in 2023 increased 18.37% year on year; passenger occupancy rates of the three major airlines all recovered to more than 80% in February
Meitu's adjusted net profit in 2023 was about 370 million yuan, up 233.2% year on year; Longhu Group's total contract sales amount for February was 5.75 billion yuan.
Futu NewsMar 18 08:04
Dongyao Pharmaceutical-B (01875.HK) announced annual results, a sharp increase in revenue of 77%, and the group's hematopoietic capacity continued to increase
Gelonghui March 15 | Dongyao Pharmaceutical-B (01875.HK) announced that in 2023, the Group's revenue was RMB 780,629 thousand, an increase of 77% over the previous year. Among them, product sales revenue was RMB 630,207 thousand, an increase of 107% over the previous year. The main contribution was due to a significant increase in sales performance of the core product Park Xinting (bevacizumab injection). CDMO/CMO business revenue was RMB 140,898 thousand, up 94% year over year. Due to no one-time authorization income for the full year of 2023 (RMB 54,151 thousand for the full year of 2022)
Gelonghui FinanceMar 15 22:28
TOT BIOPHARM-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Futu NewsMar 15 22:08 · Announcements
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
券商中國Mar 13 21:18
No Data
No Data